Publications

Titlesort descending Year
Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. 2013
Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled mu 2022
Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency 2020
Repurposing Avermectins and Milbemycins against Mycobacteroides abscessus and Other Nontuberculous Mycobacteria 2021
Repurposing clinically approved cephalosporins for tuberculosis therapy. 2016
Sanfetrinem, repurposing an oral beta-lactam with intracellular activity for the treatment of tuberculosis 2019
Targeting Tuberculosis: Existing drugs can - and should - be repurposed to fight neglected diseases. 2017
Targeting Tuberculosis: Existing drugs can – and should – be repurposed to fight neglected diseases. 2017
The FICI paradigm: correcting flaws in antimicrobial in vitro synergy screens at their inception. 2019
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme 2022
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening 2018
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening 2019